March 27, 2018MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

March 12, 2018 - MYR Pharma Completes MYR 202 Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

February 22, 2018MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B

October 22, 2017 - MYR Pharma presents positive interim results in MYR 202 clinical trial

July - September, 2017 – Several review articles highlight Myrcludex B as a strong contender in the treatment of Hepatitis D and B:

May 26, 2017Myrcludex B becomes one of five new drugs to receive PRIME (PRIority MEdicines) designation in 2017

May 2, 2017Myrcludex B potential in the treatment of Hepatitis D reviewed in Current Opinion in Virology

May 25, 2016Initiation of MYR 203

April 24, 2016 - First results of chronic Hepatitis D treatment with Myrcludex B are published in Journal of Hepatology

April 24, 2016Results of first-in-human application of Myrcludex B are reported in Jounral of Hepatology